A study by researchers from the University of Colorado showed that the widely used weight-loss drug semaglutide may help improve the reproductive health of women with polycystic ovary syndrome.
Scientists pointed out that polycystic ovary syndrome is one of the most common hormonal disorders among women of reproductive age. It is associated with irregular menstrual cycles, high levels of male hormones in a woman's blood, difficulty ovulating, and an increased risk of infertility. Moreover, many women with this syndrome suffer from obesity and metabolic disorders, which negatively affect their reproductive functions.
To discover the effect of the drug semaglutide on the fertility of women with polycystic ovary syndrome, researchers analyzed data from participants in the RESTORE clinical trial, aged between 12 and 35 years, and focused on women who achieved at least a 10% weight loss while taking this drug. They noted that this group experienced an improvement in reproductive outcomes faster than expected, which prompted them to publish the initial results of the study.
The researchers point out that semaglutide has the potential to address two major problems in polycystic ovary syndrome simultaneously: weight gain and ovu selation disorders. However, the study is still ongoing, and the current data are considered preliminary.
